We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

93 hedge funds and large institutions have $648M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more capital invested

Capital invested by funds: $302M → $648M (+$346M)

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

22% more funds holding

Funds holding: 76 → 93 (+17)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

77% less call options, than puts

Call options by funds: $3.68M | Put options by funds: $15.8M

Holders
93
Holders Change
+17
Holders Change %
+22.37%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
41
Increased
16
Reduced
27
Closed
24
Calls
$3.68M
Puts
$15.8M
Net Calls
-$12.1M
Net Calls Change
-$12.1M

Top Buyers

Rank Fund Capital Flow
1
AAM
Alpine Associates Management
Florida
+$10.9M
2
TAL
TIG Advisors LLC
New York
+$8.99M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$7.55M
4
Millennium Management
Millennium Management
New York
+$6.64M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$19.5M
2
HighTower Advisors
HighTower Advisors
Illinois
-$11.5M
3
BlackRock
BlackRock
New York
-$9.81M
4
Morgan Stanley
Morgan Stanley
New York
-$7.86M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
76
BNP Paribas Financial Markets
France
$64.4K -$7.19K -567 -17%
FC
77
FORA Capital
Florida
$64K +$35.1K +2,772 New
UBS Group
78
UBS Group
Switzerland
$56K -$833K -65,731 -96%
Bank of Montreal
79
Bank of Montreal
Ontario, Canada
$50K +$19.3K +1,523 +231%
EP
80
Eudaimonia Partners
Tennessee
$42K +$22.8K +1,800 New
Legal & General Group
81
Legal & General Group
United Kingdom
$40K -$558 -44 -2%
AIP
82
Ameritas Investment Partners
Nebraska
$28K – – –
Group One Trading
83
Group One Trading
Illinois
$28K +$13.9K +1,100 +1,100%
Royal Bank of Canada
84
Royal Bank of Canada
Ontario, Canada
$27K +$3.44K +271 +30%
Osaic Holdings
85
Osaic Holdings
Arizona
$23K +$12.7K +1,000 New
TRCT
86
Tower Research Capital (TRC)
New York
$19K -$109K -8,630 -91%
PCM
87
Penserra Capital Management
California
$18K +$6.25K +493 +169%
MTCM
88
Mint Tower Capital Management
Netherlands
$3K +$190K +15,000 New
SBL
89
Sargent Bickham Lagudis
Colorado
$2K – – –
Daiwa Securities Group
90
Daiwa Securities Group
Japan
$1K -$1.62K -128 -67%
Walleye Capital
91
Walleye Capital
New York
$347 +$190K +15,025 New
AIG
92
American International Group
New York
$192 -$3.02K -238 -3%
RCM
93
RA Capital Management
Massachusetts
– -$19.5M -1,915,568 Closed
HighTower Advisors
94
HighTower Advisors
Illinois
– -$11.5M -1,130,000 Closed
Fidelity Investments
95
Fidelity Investments
Massachusetts
– -$6.87M -674,800 Closed
WP
96
Woodline Partners
California
– -$3.92M -385,480 Closed
AG
97
Artal Group
Luxembourg
– -$3.08M -302,750 Closed
CI
98
Clal Insurance
Israel
– -$2.97M -292,000 Closed
Federated Hermes
99
Federated Hermes
Pennsylvania
– -$1.94M -190,034 Closed
OFM
100
Omega Fund Management
Massachusetts
– -$1.91M -187,538 Closed
1 2 3
4
5

PRVL Hedge Fund Activity: Q4 2020 in Review

93 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2020, worth a combined $648M — up 115% from $302M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PRVL positions and 24 closed out — a net gain of 17 holders — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Alpine Associates Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.5M sold.

  • 93 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2020, up from 76 in Q3 2020.
  • Funds reported $648M of Prevail Therapeutics Inc. Common Stock stock for Q4 2020, up 115% quarter-over-quarter.
  • 41 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2020 and 24 closed out, a net change of +17 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2020 was Alpine Associates Management, an estimated $10.9M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2020.